Envista Holdings Co. (NYSE:NVST – Get Free Report) has received a consensus recommendation of “Hold” from the fourteen brokerages that are currently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $19.59.
NVST has been the subject of several research analyst reports. Stifel Nicolaus dropped their target price on shares of Envista from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, July 30th. Needham & Company LLC restated a “hold” rating on shares of Envista in a report on Thursday, August 8th. JPMorgan Chase & Co. lowered shares of Envista from an “overweight” rating to a “neutral” rating and lowered their price objective for the stock from $23.00 to $16.00 in a report on Thursday, August 8th. Robert W. Baird lowered their price objective on shares of Envista from $19.00 to $17.00 and set a “neutral” rating for the company in a report on Monday, July 22nd. Finally, Evercore ISI boosted their price objective on shares of Envista from $18.00 to $23.00 and gave the stock an “outperform” rating in a report on Monday, September 23rd.
Get Our Latest Stock Analysis on NVST
Envista Price Performance
Envista (NYSE:NVST – Get Free Report) last announced its earnings results on Wednesday, August 7th. The company reported $0.11 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.27 by ($0.16). Envista had a negative net margin of 52.25% and a positive return on equity of 4.86%. The company had revenue of $633.10 million for the quarter, compared to the consensus estimate of $646.88 million. During the same quarter in the previous year, the firm earned $0.43 earnings per share. The company’s revenue for the quarter was down 4.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Envista will post 0.69 EPS for the current fiscal year.
Insider Buying and Selling
In other news, CFO Eric D. Hammes bought 24,532 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The shares were bought at an average cost of $16.33 per share, with a total value of $400,607.56. Following the completion of the purchase, the chief financial officer now directly owns 24,532 shares in the company, valued at $400,607.56. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.30% of the stock is owned by insiders.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Envista by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 17,167,767 shares of the company’s stock valued at $413,056,000 after purchasing an additional 944,596 shares during the period. Ariel Investments LLC increased its position in Envista by 11.0% during the 2nd quarter. Ariel Investments LLC now owns 9,871,152 shares of the company’s stock valued at $164,157,000 after purchasing an additional 978,952 shares during the period. Nuance Investments LLC increased its position in Envista by 47.2% during the 2nd quarter. Nuance Investments LLC now owns 7,038,313 shares of the company’s stock valued at $117,048,000 after purchasing an additional 2,256,993 shares during the period. American Century Companies Inc. increased its position in Envista by 15.4% during the 2nd quarter. American Century Companies Inc. now owns 6,726,651 shares of the company’s stock valued at $111,864,000 after purchasing an additional 897,141 shares during the period. Finally, Jupiter Asset Management Ltd. purchased a new position in Envista during the 2nd quarter valued at $69,534,000.
Envista Company Profile
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
Further Reading
- Five stocks we like better than Envista
- What Are the U.K. Market Holidays? How to Invest and Trade
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- 3 Healthcare Dividend Stocks to Buy
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- Transportation Stocks Investing
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.